Repare Therapeutics (NASDAQ:RPTX) Given “Buy” Rating at HC Wainwright

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 177.78% from the stock’s current price.

Separately, Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th.

Repare Therapeutics Price Performance

RPTX stock traded up $0.11 during mid-day trading on Friday, hitting $3.60. 17,345 shares of the stock were exchanged, compared to its average volume of 161,953. The business has a fifty day moving average price of $3.34 and a 200 day moving average price of $3.39. Repare Therapeutics has a 12 month low of $2.71 and a 12 month high of $8.49. The stock has a market capitalization of $152.82 million, a price-to-earnings ratio of -2.20 and a beta of 0.72.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.03. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $4.02 million. As a group, equities analysts forecast that Repare Therapeutics will post -2.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Repare Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. increased its stake in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after purchasing an additional 4,000 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock worth $366,000 after purchasing an additional 5,673 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after purchasing an additional 8,809 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Repare Therapeutics in the 2nd quarter worth $110,000. Finally, Acadian Asset Management LLC increased its stake in shares of Repare Therapeutics by 53.5% in the 1st quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock worth $625,000 after purchasing an additional 46,648 shares in the last quarter. 85.09% of the stock is owned by institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.